Literature DB >> 1316144

Expression of human foamy virus is differentially regulated during development in transgenic mice.

A Aguzzi1, K Bothe, I Anhauser, I Horak, A Rethwilm, E F Wagner.   

Abstract

The human foamy virus (HFV) is a recently characterized member of the spumavirus family. Although no diseases have been unequivocally associated with HFV infection, expression of HFV regulatory genes in transgenic mice induces a characteristic acute neurodegenerative disease and a myopathy. To better characterize the sequence of events leading to disease, and to gain a better understanding of the underlying pathogenetic mechanisms, we have analyzed in detail the transgene expression pattern during development. Transcription of a construct containing all regulatory elements and ancillary genes of HFV was analyzed by in situ hybridization and was shown to occur in two distinct phases. At midgestation, low but widespread expression was first detected in cells of extraembryonic tissues. Later, various tissues originating from embryonic mesoderm, neuroectoderm, and neural crest transcribed the transgene at moderate levels. However, expression decreased dramatically during late gestation and was suppressed shortly after birth. After a latency period of up to 5 weeks, transcription of the transgene resumed in single cells distributed irregularly in the central nervous system and in the skeletal muscle. By the age of 8 weeks, an increasing number of cells displayed much higher expression levels than in embryonic life and eventually underwent severe degenerative changes. These findings demonstrate that HFV transgene expression is differentially regulated in development and that HFV cytotoxicity may be dose-dependent. Such biphasic pattern of expression differs from that of murine retroviruses and may be explained by the specificity of HFV regulatory elements in combination with cellular factors. Future studies of this model system should, therefore, provide novel insights in the mechanisms controlling retroviral latency.

Entities:  

Mesh:

Year:  1992        PMID: 1316144

Source DB:  PubMed          Journal:  New Biol        ISSN: 1043-4674


  9 in total

Review 1.  Grafting mouse brains: from neurocarcinogenesis to neurodegeneration.

Authors:  A Aguzzi
Journal:  EMBO J       Date:  1998-11-02       Impact factor: 11.598

2.  Reactivation of a complex retrovirus is controlled by a molecular switch and is inhibited by a viral protein.

Authors:  Christopher D Meiering; Maxine L Linial
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

3.  Assignment of mouse nicein genes to chromosomes 1 and 18.

Authors:  D Aberdam; M F Galliano; M G Mattei; A Pisani-Spadafora; J P Ortonne; G Meneguzzi
Journal:  Mamm Genome       Date:  1994-04       Impact factor: 2.957

Review 4.  Historical perspective of foamy virus epidemiology and infection.

Authors:  C D Meiering; M L Linial
Journal:  Clin Microbiol Rev       Date:  2001-01       Impact factor: 26.132

Review 5.  Transgenic and knockout mice in the study of neurodegenerative diseases.

Authors:  A Aguzzi; S Brandner; S Marino; J P Steinbach
Journal:  J Mol Med (Berl)       Date:  1996-03       Impact factor: 4.599

6.  A serological survey of bovine syncytial virus in Ontario: associations with bovine leukemia and immunodeficiency-like viruses, production records, and management practices.

Authors:  R M Jacobs; F L Pollari; W B McNab; B Jefferson
Journal:  Can J Vet Res       Date:  1995-10       Impact factor: 1.310

7.  Human foamy virus proteins accumulate in neurons and induce multinucleated giant cells in the brain of transgenic mice.

Authors:  A Aguzzi; E F Wagner; K O Netzer; K Bothe; I Anhauser; A Rethwilm
Journal:  Am J Pathol       Date:  1993-04       Impact factor: 4.307

8.  Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay.

Authors:  S F Yu; M L Linial
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

9.  A defective human foamy provirus generated by pregenome splicing.

Authors:  A Saïb; J Périès; H de Thé
Journal:  EMBO J       Date:  1993-11       Impact factor: 11.598

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.